Compare NWBI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWBI | MESO |
|---|---|---|
| Founded | 1896 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | NWBI | MESO |
|---|---|---|
| Price | $12.48 | $19.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $15.00 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 868.2K | 191.8K |
| Earning Date | 01-23-2026 | 08-28-2025 |
| Dividend Yield | ★ 6.54% | N/A |
| EPS Growth | ★ 13.78 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $564,562,000.00 | $17,198,000.00 |
| Revenue This Year | $7.91 | $465.44 |
| Revenue Next Year | $9.01 | $75.37 |
| P/E Ratio | $14.16 | ★ N/A |
| Revenue Growth | 15.71 | ★ 191.39 |
| 52 Week Low | $10.75 | $9.61 |
| 52 Week High | $14.64 | $22.00 |
| Indicator | NWBI | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 60.81 | 70.18 |
| Support Level | $12.14 | $16.43 |
| Resistance Level | $12.54 | $17.65 |
| Average True Range (ATR) | 0.24 | 0.66 |
| MACD | 0.08 | 0.36 |
| Stochastic Oscillator | 96.43 | 95.46 |
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.